Buck CEO Brian Kennedy Meets with Biotech and Pharma Companies in Tokyo

Recent Trip to Asia Highlights Aging Demographics

January 3, 2012  Novato, CA Forging a connection between the Buck Institute for Research on Aging and biotech and pharmaceutical companies in Japan makes total sense in light of demographics. Japan, with today’s largest share of the world’s elderly population, will see its percentage of those 60 and over rise from 27 percent to 44 percent in 2050.

“There is an increased urgency in Japan to focus on efforts to slow the aging process thereby delaying a host of age-related diseases,” said Brian K. Kennedy, PhD, Buck Institute President and CEO.  “I am excited about potential partnerships with those in Japan who appreciate the work now underway at the Buck.”

In a trip organized by Buck Institute Board of Trustee Shahab Fatheazam, Kennedy recently traveled to Tokyo and met with officials from several companies, including Sumito Corporation, Thomson Reuters, Kao Corporation, Lincoln International, NEC and Cerberus Capital Management among others.  "Japan is at the threshold of looking outward for business and other opportunities,” said Fatheazam who is Managing Director, Head of Healthcare for Lincoln International. “The Buck initiative was very timely in establishing its name and the opportunities associated with it, to Japanese corporate and other sponsors. With follow up, this will accrue to the benefit of both parties."

Kennedy also visited the Genome Institute of Singapore and the Tsao Foundation for Healthy Aging, also located in Singapore.   Kennedy also visited his lab at the Aging Research Institute at Guangdong Medical College in China, where he is a visiting professor.  His research in China is focused on basic mechanisms governing aging and understanding links between premature aging disorders and the normal aging process.

“Japan stands out for having the longest-lived population in the world,” said Kennedy. “There’s much we can learn about their genetics, lifestyle choices and social support systems in our work to extend healthspan. I look forward to building on the relationships we began during this recent trip.”

About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first and foremost independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, macular degeneration, diabetes and stroke.  In their collaborative research, they are supported by the most recent developments in genomics, proteomics and bioinformatics. For more information: www.thebuck.org.

Change text size: